亚太核医学市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

亚太核医学市场按产品(诊断和治疗)、应用和地理划分

市场快照

Asia Pacific Nuclear-1
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 10 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

亚太地区核医学市场主要受癌症和心脏病事件增加、SPECT 和 PET 应用增加以及公众对医疗保健意识增强等因素的推动。

癌症和心脏病发病率的增加是市场的主要驱动力。核医学在治疗心脏病和癌症疾病方面显示出巨大的潜力。根据癌症指数,估计亚洲地区每年有 6,763,000 例新病例和 4,499,500 人死于癌症。心脏病学应用将继续展示市场的强劲增长。

此外,监管要求对转化研究和临床调查构成障碍。例如,在印度,核医学产品的所有批准均由原子能监管委员会 (AERB) 授予,包括诊断性放射性药物和放射治疗在内,都经过 AERB 的监管程序。这表明了对核医学监管的重视,使得监管过程变得更加严格。

报告范围

根据报告的范围,核医学属于分子成像领域,其中涉及使用极少量的放射性物质(放射性药物)来诊断和治疗疾病。在核医学成像中,放射性同位素是由连接到计算机的特殊类型的相机检测的,这反过来又提供了被检查身体区域的非常精确的图片。

By Product
By Diagnostics
Single Photon Emission Computed Tomography (SPECT)
Positron Emission Tomography (PET)
By Therapeutics
Alpha Emitters
Beta Emitters
Brachytherapy
By Application
Cardiology
Neurology
Oncology
Other Applications
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

主要市场趋势

预计诊断部门将在预测期内显示出更好的增长。

诊断部分分为 SPECT 和 PET。PET成像放射性同位素在临床神经病学中有许多应用,涉及运动障碍、癫痫、脑肿瘤、痴呆、中风和神经元可塑性。未来的应用包括脑转移、帕金森综合征和神经退行性疾病(如阿尔茨海默病)的早期诊断。由于人们对放射性同位素的认识不断提高,癌症和心血管疾病等慢性病的发病率增加,因此预计发展中国家的放射性同位素市场将会更大。因此,由于这些因素,预计市场在预测期内将出现快速增长。

Picture4.png

竞争格局

亚太核医学市场参与者之间存在适度竞争。然而,这种竞争并不是凭借竞争性定价或产品差异化。此外,制药和生物技术行业的大公司正在利用其庞大的资本储备进入这个市场,这进一步加剧了竞争。预计未来几年,很少有中小型公司会进入市场并在亚太地区占据相当大的份额。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders

      2. 4.2.2 Increasing Demand for Biosimilar Drugs Due to Their Cost Effectiveness

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of the Diagnostic and Therapeutic Equipment and Procedures

      2. 4.3.2 Regulatory Uncertainty

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 By Diagnostics

        1. 5.1.1.1 Single Photon Emission Computed Tomography (SPECT)

        2. 5.1.1.2 Positron Emission Tomography (PET)

      2. 5.1.2 By Therapeutics

        1. 5.1.2.1 Alpha Emitters

        2. 5.1.2.2 Beta Emitters

        3. 5.1.2.3 Brachytherapy

    2. 5.2 By Application

      1. 5.2.1 Cardiology

      2. 5.2.2 Neurology

      3. 5.2.3 Oncology

      4. 5.2.4 Other Applications

    3. 5.3 Geography

      1. 5.3.1 Asia-Pacific

        1. 5.3.1.1 China

        2. 5.3.1.2 Japan

        3. 5.3.1.3 India

        4. 5.3.1.4 Australia

        5. 5.3.1.5 South Korea

        6. 5.3.1.6 Rest of Asia-Pacific

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 GE Healthcare

      2. 6.1.2 Lantheus Medical Imaging, Inc.

      3. 6.1.3 Bracco Diagnostic Inc.

      4. 6.1.4 Nordion, Inc.

      5. 6.1.5 Curium

      6. 6.1.6 Siemens Healthineers AG

      7. 6.1.7 Cardinal Health, Inc.

      8. 6.1.8 NTP Radioisotopes

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Nuclear Medicine Market market is studied from 2018 - 2026.

The Asia-Pacific Nuclear Medicine Market is growing at a CAGR of 10% over the next 5 years.

Cardinal Health, Curium SAS, Lantheus Medical Imaging, GE Healthcare, Bracco Diagnostic Inc.. are the major companies operating in Asia-Pacific Nuclear Medicine Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!